Precision Medicine Implementation

Program Details

  • Intended Audience: Consultant pharmacists of pharmacists interested in precision medicine
  • Universal Activity Number: 0012-0000-19-028-H04-P
  • Contact Hours: 15.00 Consultant/General
  • Program Fees: $299.00
  • Dates Available: 09/13/2019 to 09/13/2022
  • Activity Type: Knowledge


This program focuses on equipping pharmacists to translate pharmacogenomics science into daily practice. Renowned speakers provide practice insight on individualizing drug therapy, laboratory testing, reimbursement and other emerging precision medicine topics.

This home study course is approved by the Florida Board of Pharmacy for 15 consultant pharmacist recertification hours.


At the completion of this activity, the participant will be able to:

  • Describe the current state of knowledge and emerging trends in precision medicine in clinical practice.
  • Apply genetic and pharmacogenetic data to solve complex patient cases.
  • Use pharmacogenetic testing in a multidisciplinary primary care practice.
  • Demonstrate the case for preemptive pharmacogenomic testing in a variety of clinical settings.
  • Describe challenges and solutions for the application of precision medicine in diverse patient populations.
  • Illustrate solutions to common precision medicine implementation barriers.
  • Discuss emerging ethical, legal and social implications in precision medicine, including liability and health disparity.

Schedule of Activities and Requirements for Successful Course Completion

Review all course materials, view the recorded lectures, achieve a passing score of 70% or more on final exam, and complete the program evaluation. 

Program Faculty

A full list of the program faculty can be found on the speaker page.

Disclosure Statement

The following speakers, reviewers, and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Meghan J. Arwood, Pharm.D., BCPS
Jeffrey Bishop, Pharm.D., M.S., BCPS, FCCP
Adam H. Buchanan, M.S., MPH, CGC
Larisa Cavallari, Pharm. D.
Emily Cicali, Pharm.D.
Christopher R. Cogle, M.D.
Rhonda Cooper-DeHoff, Pharm.D., M.S., FAHA, FACC
Kristine Crews, Pharm.D.
Joshua Charles Denny, MD, MS
Julio Duarte, Pharm.D., Ph.D.
Ben Quang Duong, PharmD
Susanne Haga, Ph.D.
Carol Horowitz, M.D. MPH

Peter J. Hulick, M.D., MMSc
Julie Johnson, Pharm.D
Jason H. Karnes, Pharm.D., Ph.D.
Ann Moyer, M.D., Ph.D.
David R. Nelson, M.D.
Alexander Parker, Ph.D., M.S.
Hari K. Parvataneni, M.D.
Sonja A. Rasmussen, M.D., M.S.
Marci Schwartz, M.S., LGC
Maxwell Smith III, PharmD, BCPS
Lauren B. Solberg, J.D., MTS
Christine Walko, Pharm.D., BCOP, FCCP
Kristin Wiisanen, Pharm.D., FAPhA

The following speakers, reviewers, and planning committee members have disclosed the following:

  • Euan A. Ashley, BSc, MB, ChB, FRCP, DPhil, FAHA, FACC, FESC has disclosed that he is a consult for Myokardia.
  • William S. Dalton, M.D., Ph.D.  has disclosed that he is employed by M2Gen, a for-profit health information solutions company.  
  • David DeRemer, Pharm.D., BCOP, FCCP has disclosed that he is on the advisory board for Amgen.
  • Mark Dunnenberger, Pharm.D., BCPS has disclosed that he is a consultant for Veritas Genetics and Admera Health.
  • Mia Mehanna, MS, has disclosed that she receives grant/research support from the National Institute of Health Pharmaogenetics Research.
  • Howard McLeod, PharmD. has disclosed he is a consultant for Viecure, affiliated with the Genentech speakers bureau, and a shareholder for Cancer Genetics and Interpares Biomedicine.
  • Duane A. Mitchell, MD, PhD has disclosed that he receives grant/research support from Immunomic Therapeutics and is a consultant for Bristol Myers-Squibb, Tocagen, and Oncarus.  He also holds shares in iOncologi, Inc., and receives other financial or material support from Annias Immunotherapeutics and Celldex Therapuetics

Credit Reporting

  • The University of Florida College of Pharmacy will report CPE credit to CPE Monitor and CE Broker when applicable. If you would like a paper statement of credit, you may print it from your NABP e-profile.
  • All pharmacists and pharmacy technicians maintain their own license and/or certification and it is their responsibility to follow up with the Office of Continuing Education at the University of Florida if any CE credit discrepancies are found.
  • It is at the University’s discretion to award or deny credit to a late claiming participant (i.e. after 60 days of the participant engaging in a CPE activity) as it is the University’s CE activity and the provider needs to ensure the requirements necessary for credit are successfully completed.
  • The University may request access to CPE Monitor® if the activity in question occurred within the previous 6 months and with an appropriate reason for access, i.e. power outage, etc.

Program Financial Support

This course received no financial program support.

Computer Requirements

Computer and Internet access are required to complete this course. Course content is provided via Canvas.

The minimum hardware, software and internet requirements for Canvas can be found here.


Refund Policy for CE Courses

Privacy and Confidentiality Policy


This course in its entirety is copyrighted by the University of Florida Continuing Pharmacy Education and may not be duplicated or reproduced for any other purpose without specific written permission.

Contact Us

For questions or more information, please contact our office.

The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.